Celltrion bought two autoimmune disease treatment candidates owned by Kaigene for an upfront payment of about 11.4 billion won. Celltrion said on the 4th that it signed an exclusive license agreement ...

Celltrion said Tuesday it acquired French health care firm Gifrer, securing a sales network capable of responding swiftly to changes in local ...

SEOUL (Reuters) -Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million. In a ...

South Korea's Celltrion Inc. said Tuesday it acquired the entire stake in French health care company Gifrer in a bid to expand its presence in the European Union. The biopharmaceutical company did not ...

TORONTO, Ontario, November 27, 2025--(BUSINESS WIRE)--Celltrion, Inc. today announced that Health Canada has approved Eydenzelt ®, a biosimilar referencing Eylea ® (aflibercept 2mg), in both vial and ...

Celltrion announced on May 13 that it has been included for the second consecutive year in the Dow Jones Best-in-Class (DJ BIC) World Index, a global ...

Celltrion said Tuesday it acquired French health care company Gifrer as the Korean biopharmaceutical firm expands its European business to include generics and ...

Celltrion said Friday that Zymfentra, the world’s only subcutaneous formulation of infliximab, saw record-breaking ...

South Korean pharmaceutical f company Celltrion on Wednesday reported first-quarter sales of $790 million, up 36% from the ...

As we have previously reported, in November 2023 Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed complaints against Celltrion, Samsung Bioepis and Formycon (collectively, “the Defendants”) in the ...

Celltrion, a South Korean biopharma, said that despite receiving Complete Response Letters from the FDA, it remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and ...

Celltrion’s range of COVID-19 diagnostic kits have once again fallen under the FDA’s microscope, just weeks after the regulator cracked down on sales of a version of the company's rapid antigen test ...